Non-Alcoholic Fatty Liver Disease Clinical Trials in New York, New York

6 studies are recruiting for non-alcoholic fatty liver disease in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

   This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.

   Stage

   Phase 3

   Ages

   18 to 75

   Site

   GSK Investigational Site, New York, New York

   Locations

   66 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT07221188 on ClinicalTrials.gov

2. Human Models of Selective Insulin Resistance: Alpelisib, Part I

   The goal of this clinical trial is to understand how the blood sugar-lowering hormone insulin works in healthy adults versus those who are at risk for type 2 diabetes. The study will use a drug called alpelisib, which interferes with insulin's actions in the body, to answer the study's main questio…

   Stage

   Phase 1

   Ages

   18 to 70

   Site

   Columbia University Irving Medical Center, New York, New York

   Run by

   Columbia University

   See if you can join NCT06354088 on ClinicalTrials.gov

3. A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

   The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.

   Stage

   Phase 3

   Ages

   18 to 75

   Site

   GSK Investigational Site, New York, New York

   Locations

   91 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT07221227 on ClinicalTrials.gov

4. A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

   The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   GSK Investigational Site, New York, New York

   Locations

   30 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT06920043 on ClinicalTrials.gov

5. Effect of Insulin Lowering on Lipogenesis

   The goal of this clinical trial is to compare a one-week course of diazoxide (2 mg/kg per dose x 14 doses) and placebo in people with obesity and insulin resistance (IR) with metabolic dysfunction-associated steatotic liver disease (MASLD). The main question it aims to answer are how mitigation of …

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   Columbia University Irving Medical Center, New York, New York

   Run by

   Columbia University

   See if you can join NCT07403604 on ClinicalTrials.gov

6. Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease

   This study will assess the impact of time-restricted eating (8 hours of eating each day) with standard of care lifestyle recommendations (hypocaloric, Mediterranean diet and 30 minutes of exercise on at least 5 days/week) on the degree of fat in the liver as measured by magnetic resonance imaging.

   Stage

   Not phased

   Ages

   18 to 65

   Site

   Weill Cornell Medicine, New York, New York

   Run by

   Weill Medical College of Cornell University

   See if you can join NCT05332613 on ClinicalTrials.gov